Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

Key facts

Sponsor

University of Oxford

Principal Investigator

Alexander D Douglas

Jenner Institute

Intervention

ChAdOx2 RabG(biological)

Enrollment

18 target

Eligibility

18-65 years · All sexes

Timeline

2020 – 2024

Study locations (1)

• CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rabies

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07500207
  A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
  Changchun BCHT Biotechnology Co.
• ACTIVE NOT RECRUITINGPHASE3NCT07275645
  A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
  Ab&B Bio-tech Co., Ltd.JS
• ENROLLING BY INVITATIONPHASE1NCT07338786
  A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)
  Changchun BCHT Biotechnology Co.
• RECRUITINGPHASE1NCT07021703
  A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
  Ningbo Rongan Biological Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT06998004
  A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
  AstriVax Therapeutics
• ENROLLING BY INVITATIONPHASE3NCT05545371
  Prevention of Rabies With Four Doses of Rabies Vaccine
  Changchun Zhuoyi Biological Co., Ltd
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04270838
  A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
  University of Oxford

See all trials for Rabies →